Overview

PF-00299804 As A Single Agent, In Patients With Advanced Non-Small Cell Lung Cancer Who Have Failed Chemotherapy And Erlotinib

Status:
Completed

Trial end date:
2012-06-11

Target enrollment:

Participant gender:

Summary

To assess the antitumor efficacy measured by the objective response rate of oral PF-00299804 taken daily, as single agent in patients with advanced NSCLC who failed at least one chemotherapy + erlotinib.

Phase:

Phase 2

Details

Lead Sponsor:

Pfizer

Treatments:

Erlotinib Hydrochloride